Metabolic-Only Criteria in Pediatric High-Risk (HR) cHL: A Review of Reduced Radiotherapy (RT) Exposure in HLHR13 and cHOD17 TrialsJohn T. Lucas, Matthew J. Ehrhardt, Yinmei Zhou et al.|Klinische Pädiatrie|2025Cited by 0
Pediatric Hodgkin Consortium Trial Updates: Response-based omission of radiotherapy (RT) for the majority of young people with Hodgkin lymphoma (HL) while maintaining excellent outcomes: Five-year results of HOD08 for low-risk (LR) HL and initial results of cHOD17 high-risk (HR) stratumAngela M. Feraco, Matthew J. Ehrhardt, Jamie E. Flerlage et al.|Klinische Pädiatrie|2025Cited by 0